News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
ESMO – In an interim analysis presented at ESMOBreast24 of atezolizumab and sacituzumab in locally advanced or metastatic triple-negative breast cancer
Photo taken from ESMO/LinkedIn
May 24, 2024, 01:43

ESMO – In an interim analysis presented at ESMOBreast24 of atezolizumab and sacituzumab in locally advanced or metastatic triple-negative breast cancer

ESMO shared a post on LinkedIn:

“In an interim analysis presented at ESMOBreast24, first-line treatment with the combination of the PD-L1 inhibitor atezolizumab and sacituzumab govitecan showed a higher objective response rate compared to control in patients with previously untreated PD-L1 positive locally advanced or metastatic triple-negative breast cancer.”

Read further.
Source: ESMO/LinkedIn

cancer ESMO ESMOBreast24 Metastatic Triple Negative Breast Cancer OncoDaily Oncology
Special Coverage
Blog
Dec 21, 2024, 11:30
Kyaw Thein: Tissue-Agnostic Drug Development in Cancer
Dialogues
Dec 21, 2024, 11:29
Beyond the Cancer Diagnosis: Dialogue with Marianne Arab, Hosted by Adrian Pogacian
Blog
Dec 21, 2024, 11:27
Aleix Prat: Carlos Fernandez de Larrea has been appointed as a Professor at the University of Barcelona
Blog
Dec 21, 2024, 11:25
Canadian Cancer Society - Natalie Wild's caregiver story
Blog
Dec 21, 2024, 11:24
Christy Brown: How many things can you dread more than 'your child has aggressive brain cancer?'
Blog
Dec 21, 2024, 11:18
Jose Fernando Moura: Pivotal SABCS24 summary hosted by Cancer Network
Blog
Dec 21, 2024, 11:18
Jérôme Salomon: President Macron, WHO Director-General and global health leaders inaugurate WHO Academy
Blog
Dec 21, 2024, 11:17
ChatGPT-Like AI Tool Promises to Speed Treatment Advances and Free Doctors’ Time by Matching Patients with Clinical Trials
Blog
Dec 21, 2024, 11:14
Mediamedic - Wenbin Zhou on Pyrotinib-based regimen in HER2-positive breast cancer
Blog
Dec 21, 2024, 11:12
Didier Verhoeven: Comparing survival in breast cancer in Belgian Breast Centres
Blog
Dec 21, 2024, 11:06
Every great journey has its finale - eCAN Joint Action
Drugs
Dec 21, 2024, 10:38
Hanna Foster: Market cap and Revenue of Cancer NGS Drugs providers in 2024